(Q34112917)

31 July 2017

1 reference

title

The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? (English)

1 reference

31 July 2017

0 references

Banerjee D

1

1 reference

31 July 2017

Stableforth D

series ordinal

2

1 reference

31 July 2017

publication date

1 November 2000

1 reference

31 July 2017

1 reference

31 July 2017

volume

60

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

1053-1064

1 reference

Inhalation of antibiotics in cystic fibrosis.

31 July 2017

cites work

1 reference

12 December 2020

Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis

1 reference

12 December 2020

Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis

1 reference

12 December 2020

Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis

1 reference

12 December 2020

Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

1 reference

12 December 2020

An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre

1 reference

12 December 2020

Pseudomonas cepacia infection in cystic fibrosis

1 reference

12 December 2020

Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects.

1 reference

12 December 2020

Chronic Burkholderia cepacia bronchiectasis in a non-cystic fibrosis individual

1 reference

12 December 2020

The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia

1 reference

12 December 2020

Evaluation of a once-daily netilmicin regimen in the treatment of cystic fibrosis

1 reference

12 December 2020

Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function

1 reference

12 December 2020

Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of t

1 reference

12 December 2020

In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis

1 reference

12 December 2020

In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens

1 reference

12 December 2020

Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995).

1 reference

12 December 2020

Aminoglycoside induced ototoxicity in patients with cystic fibrosis

1 reference

12 December 2020

Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis

1 reference

12 December 2020

Nebulisers for bronchiectasis

1 reference

12 December 2020

Adverse reactions to piperacillin in patients with cystic fibrosis

1 reference

12 December 2020

Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward

1 reference

12 December 2020

Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa

1 reference

12 December 2020

Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection

1 reference

12 December 2020

Differences in the concentrations of small, anionic, antimicrobial peptides in bronchoalveolar lavage fluid and in respiratory epithelia of patients with and without cystic fibrosis.

1 reference

12 December 2020

Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis

1 reference

12 December 2020

Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group.

1 reference

12 December 2020

Antimicrobial peptides as mediators of epithelial host defense

1 reference

12 December 2020

Nebulised antibiotics for adults with cystic fibrosis

1 reference

12 December 2020

Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis

1 reference

12 December 2020

Once-daily gentamicin: translating theory into practice

1 reference

12 December 2020

Burkholderia cepacia: medical, taxonomic and ecological issues

1 reference

12 December 2020

Increasing dose regimen in children with reactions to ceftazidime

1 reference

12 December 2020

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

1 reference

12 December 2020

Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey.

1 reference

12 December 2020

Haemolytic anaemia following treatment with piperacillin in a patient with cystic fibrosis

1 reference

12 December 2020

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

12 December 2020

An 8 year Microbe Base survey of the epidemiology, frequency and antibiotic susceptibility of Pseudomonas aeruginosa hospital isolates in the United Kingdom

1 reference

12 December 2020

Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom

1 reference

12 December 2020

Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission

1 reference

12 December 2020

Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis

1 reference

12 December 2020

Pseudomonas cepacia in cystic fibrosis

1 reference

12 December 2020

In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections

1 reference

12 December 2020

Microbiology of cystic fibrosis lung infections: themes and issues

1 reference

12 December 2020

In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood

1 reference

12 December 2020

Pseudomonas cepacia infection in cystic fibrosis: an emerging problem

1 reference

12 December 2020

Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections

1 reference

12 December 2020

Four years' experience of intravenous colomycin in an adult cystic fibrosis unit

1 reference

12 December 2020

Aminoglycosides--50 years on

1 reference

12 December 2020

Cystic fibrosis: antibiotic prescribing practices in the United Kingdom and Eire

1 reference

12 December 2020

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

1 reference

12 December 2020

Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic

1 reference

12 December 2020

10.2165/00003495-200060050-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1047297596

0 references

1 reference